Cancer treatment reviews最新文献

{"title":"Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation","authors":"Manqi Hua ,&nbsp;Fei Xiong ,&nbsp;Shan Chong ,&nbsp;Zhuo Zhang ,&nbsp;Qianxin Liu ,&nbsp;Jingyi Hou ,&nbsp;Zhiqi Zhang ,&nbsp;Zhichun Gu ,&nbsp;Xiangli Cui ,&nbsp;Yimin Cui ,&nbsp;Ling Xu ,&nbsp;Qian Xiang","doi":"10.1016/j.ctrv.2024.102827","DOIUrl":"10.1016/j.ctrv.2024.102827","url":null,"abstract":"<div><h3>Background</h3><p>Recently, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have emerged as a novel treatment strategy for breast cancer. However, increasing reports of CDK4/6i-associated venous thromboembolism (VTE) have garnered attention. This study assessed CDK4/6i-associated VTE in breast cancer, and examined the effect of CDK4/6i on platelet/coagulation function for the first time <em>in vitro</em>.</p></div><div><h3>Methods</h3><p>PubMed and Embase databases were searched for studies published from the establishment of the database to December 31, 2022 for randomized controlled trials (RCTs) and real-world studies of CDK4/6i in patients with breast cancer, and the data obtained from the included studies were used for <em>meta</em>-analysis. A disproportionality analysis by extracting adverse drug reaction signals of CDK4/6i-associated VTE from the FDA Adverse Event Reporting System (FAERS) database was also conducted. Additionally, the <em>in vitro</em> effect of CDK4/6i on platelet function was assessed based on platelet aggregation tests and flow cytometry, and coagulation function was assessed based on the blood clotting function test.</p></div><div><h3>Findings</h3><p>A total of 16,903 patients in 13 RCTs and 6,490 patients in 9 real-world studies were included in the <em>meta</em>-analysis. In RCTs, VTE occurred in 193 (2.1 %) and 55 (0.7 %) patients in the CDK4/6i and control groups, respectively. In real-world studies, the aggregate incidence rate of VTE was 4.2 % (95 % CI: 2.1, 6.3). The <em>meta</em>-analysis of RCTs revealed that abemaciclib (Odds ratio [OR]: 4.40 [95 % CI: 2.74,7.05], p &lt; 0.001) and palbociclib (OR: 2.35 [95 % CI: 1.34, 4.12], p &lt; 0.01) significantly increased the risk of VTE in patients with breast cancer compared to placebo. FAERS database analysis revealed that abemaciclib (reporting odds ratio [ROR]: 1.63 [95 % CI: 1.36, 1.97]; IC₀₂₅: 0.67) and ribociclib (ROR: 1.17 [95 % CI: 1.0, 1.39]; IC₀₂₅: 0.18) demonstrated a significantly increased signal of VTE. Similarly, findings from <em>in vitro</em> experiments demonstrated that abemaciclib enhanced agonist-induced platelet activation, especially when collagen was used as the inducer, and this effect became more prominent with increasing its concentration.</p></div><div><h3>Interpretation</h3><p>Use of abemaciclib may increase the risk of VTE in patients with breast cancer, which may be partially attributed to the effect of abemaciclib on platelet function. Close monitoring of VTE occurrence is highly recommended while using abemaciclib, especially in patients at a high risk of VTE.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"130 ","pages":"Article 102827"},"PeriodicalIF":9.6,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001555/pdfft?md5=900de26a15033f6cea82b631e4857ea1&pid=1-s2.0-S0305737224001555-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142232926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development","authors":"Carla Corvaja,&nbsp;Antonio Passaro,&nbsp;Ilaria Attili,&nbsp;Pamela Trillo Aliaga,&nbsp;Gianluca Spitaleri,&nbsp;Ester Del Signore,&nbsp;Filippo de Marinis","doi":"10.1016/j.ctrv.2024.102824","DOIUrl":"10.1016/j.ctrv.2024.102824","url":null,"abstract":"<div><div>Third-generation EGFR tyrosine kinase inhibitor (TKIs) have revolutionized the treatment landscape for patients with non-small cell lung cancer (NSCLC) harboring <em>EGFR</em> activating mutations, with improved long-term outcomes compared to first-generation TKIs. Nevertheless, disease progression inevitably occurs, limiting osimertinib long-term efficacy. Indeed, the molecular biology underlying acquired resistance to first-line osimertinib is multifaceted and includes the emergence of on-target and off-target alterations. <em>EGFR</em>-C797S mutation represents the most frequent mechanism of on-target resistance and hinders drug binding to the target site. <em>EGFR</em>-independent resistance includes the activation of alternative signaling pathways, such as <em>MET</em> amplification and <em>HER2</em> mutations, and histological transformation. In this setting, chemotherapy is the current therapeutic option, with modest clinical outcomes. Therefore, the development of novel therapeutic strategies to overcome resistance to osimertinib is a major challenge. In this setting, fourth-generation TKIs are emerging as an interesting therapeutic option to overcome on-target resistance. Preclinical drug development has led to the discovery of thiazole-amid inhibitors, which activity is mediated by the allosteric inhibition of EGFR, resulting in high specificity towards mutant-EGFR. Early phase 1/2 clinical trials are ongoing to elucidate their activity also in the clinical setting. Aim of this review is to provide a state-of-the-art analysis on preclinical development of fourth-generation EGFR-TKIs and promising preliminary clinical data.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"130 ","pages":"Article 102824"},"PeriodicalIF":9.6,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes","authors":"Xinlin Liu ,&nbsp;Yunlong Song ,&nbsp;Panpan Cheng ,&nbsp;Bing Liang ,&nbsp;Dongming Xing","doi":"10.1016/j.ctrv.2024.102826","DOIUrl":"10.1016/j.ctrv.2024.102826","url":null,"abstract":"<div><p>Human epidermal growth factor receptor-2 (HER2) is overexpressed in various solid tumor types, acting as an established therapeutic target. Over the last three decades, the fast-paced development of diverse HER2-targeted agents, notably marked by the introduction of the antibody-drug conjugate (ADC), yielding substantial improvements in survival rates. However, resistance to anti-HER2 treatments continues to pose formidable challenges. The complex structure and dynamic dimerization properties of HER2 create significant hurdles in the development of novel targeted therapeutics. In this review, we synthesize the latest insights into the structural intricacies of HER2 and present an unprecedented overview of the epitope characteristics of HER2-targeted antibodies and their derivatives. Furthermore, we delve into the correlation between anti-HER2 antibody binding epitopes and their respective functions, with a particular focus on their efficacy against resistant tumors. In addition, we highlight the potential of emerging anti-HER2 agents that target specific sites or non-overlapping epitopes, poised to transform the therapeutic landscape for HER2-positive tumors in the foreseeable future.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"130 ","pages":"Article 102826"},"PeriodicalIF":9.6,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001543/pdfft?md5=47f01b152d2220670c63a55765535abc&pid=1-s2.0-S0305737224001543-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142173655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision medicine for multiple myeloma: The case for translocation (11;14)","authors":"Abdul-Hamid Bazarbachi ,&nbsp;Hervé Avet-Loiseau ,&nbsp;Jean-Luc Harousseau ,&nbsp;Ali Bazarbachi ,&nbsp;Mohamad Mohty","doi":"10.1016/j.ctrv.2024.102823","DOIUrl":"10.1016/j.ctrv.2024.102823","url":null,"abstract":"<div><p>The t(11;14) translocation is among the most prevalent cytogenetic abnormalities in multiple myeloma (MM), distinguished by its unique features and biology that have been thoroughly explored for decades. What further sets this MM subtype apart is its oscillating prognostic significance, from initially being considered a favorable alteration to intermediate risk and potential future reclassification as favorable risk. Despite not being inherently a high-risk alteration indicative of an aggressive phenotype, it appears that t(11;14)-MM is less responsive to novel agents like proteasome inhibitors and immunomodulatory drugs which have otherwise transformed the disease’s treatment landscape, perhaps partially explained by its reduced propensity for immunoglobulin production and oligosecretory nature. However, its distinct reliance on Bcl-2 has heightened its sensitivity to venetoclax. Further subclassification based on morphological and genomic characteristics could enhance our prediction models of treatment responses and enable more tailored therapeutic strategies for patients. This review aims to encapsulate the existing research evidence in this area.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"130 ","pages":"Article 102823"},"PeriodicalIF":9.6,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001518/pdfft?md5=9ad8cb5040181273687a51ff5dcbcf2a&pid=1-s2.0-S0305737224001518-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142164966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The active involvement of patients in oncology research","authors":"Ursula Ganz-Blaettler ,&nbsp;Sarah Jayne Liptrott ,&nbsp;Angela Tolotti ,&nbsp;Marco Cefalì ,&nbsp;Christine Aeschlimann ,&nbsp;Simona Berardi Vilei ,&nbsp;Ilaria Colombo ,&nbsp;Evi Hatziandreou ,&nbsp;Thanos Kosmidis ,&nbsp;Helena Linardou ,&nbsp;Rosemarie Pfau ,&nbsp;Stavroula Sgourou ,&nbsp;Cristiana Sessa","doi":"10.1016/j.ctrv.2024.102822","DOIUrl":"10.1016/j.ctrv.2024.102822","url":null,"abstract":"<div><p>The aim of this review is to provide an overview of the status of patient/public involvement (PPI) in oncology research, including definitions, regulatory aspects, ongoing clinical activities in different countries, achievements and difficulties. The 10-year activities of the Swiss Group for Clinical Cancer Research (SAKK) Patient Advisory Board are described, illustrating challenges faced and solutions in daily practice.</p><p>Even though clinical data are still limited, it appears PPI has great potential for development in oncology. The drive for precision medicine, activities of patient organizations, pharmaceutical industry interest, and strong support from regulatory agencies, are facilitators to integration of PPI throughout the drug development process. Despite the availability of guidance documents providing recommendations for the implementation of PPI, lack of human and structural resources, training for patients / caregivers and healthcare personnel, and lack of collaboration among stakeholders are some of the main barriers reported. More rigorous reporting of PPI in clinical studies is needed, including the methods to evaluate the impact of PPI and in the representation of patients as partner.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"130 ","pages":"Article 102822"},"PeriodicalIF":9.6,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001506/pdfft?md5=4e8063e08f00c74618b2d999d3672a63&pid=1-s2.0-S0305737224001506-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-Onset colorectal Cancer: From the laboratory to the clinic","authors":"Annalice Gandini ,&nbsp;Julien Taieb ,&nbsp;Hélène Blons ,&nbsp;Jeanne Netter ,&nbsp;Pierre Laurent-Puig ,&nbsp;Claire Gallois","doi":"10.1016/j.ctrv.2024.102821","DOIUrl":"10.1016/j.ctrv.2024.102821","url":null,"abstract":"<div><p>Colorectal cancer that occurs before age of 50 is defined as Early-Onset Colorectal Cancer (EOCRC). Its incidence has worryingly increased since the late 90 s and is expected to keep rising in the next future, despite Late-Onset CRC (LOCRC) is decreasing worldwide. Because of this, there is an urgent need to better understand this subset of patients in order to give them the best treatment possible. However, most of the literature is retrospective and often discordant. In this review, we aim to provide a general overview of the issue, endeavoring to highlight the current available knowledge. We decided to move from the beginning, investigating risk factors and inheritance, passing through diagnosis and clinical aspects, and to conclude with the translational part, focusing on the biology of the tumor. However, lot of questions remain open, including screening age and prognosis. Indeed, young patients tend to be treated more aggressively, even if a survival benefit has not been proven yet. Every clinician should be aware of the best practice for young people, and more translational studies are awaited in order to clarify is EOCRC represents a distinct biological entity.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"130 ","pages":"Article 102821"},"PeriodicalIF":9.6,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S030573722400149X/pdfft?md5=1b783d0c29b491404f5d9a90429ad872&pid=1-s2.0-S030573722400149X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142136256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving therapeutics and ensuing cardiotoxicities in triple-negative breast cancer","authors":"Chongyu Wang ,&nbsp;Pinchao Fan ,&nbsp;Qingqing Wang","doi":"10.1016/j.ctrv.2024.102819","DOIUrl":"10.1016/j.ctrv.2024.102819","url":null,"abstract":"<div><p>Defined as scarce expression of hormone receptors and human epidermal growth factor receptor 2, triple-negative breast cancer (TNBC) is labeled as the most heterogeneous subtype of breast cancer with poorest prognosis. Despite rapid advancements in precise subtyping and tailored therapeutics, the ensuing cancer therapy-related cardiovascular toxicity (CTR-CVT) could exert detrimental impacts to TNBC survivors. Nowadays, this interdisciplinary issue is incrementally concerned by cardiologists, oncologists and other pertinent experts, propelling cardio-oncology as a booming field focusing on the whole-course management of cancer patients with potential cardiovascular threats. Here in this review, we initially profile the evolving molecular subtyping and therapeutic landscape of TNBC. Further, we introduce various monitoring approaches of CTR-CVT. In the main body, we elaborate on typical cardiotoxicities ensuing anti-TNBC treatments in detail, ranging from chemotherapy (especially anthracyclines), surgery, anesthetics, radiotherapy to immunotherapy, with future perspectives on promising directions in the era of artificial intelligence and traditional Chinese medicine.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"130 ","pages":"Article 102819"},"PeriodicalIF":9.6,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001476/pdfft?md5=160a8e90373fe07a172687a8a34caba9&pid=1-s2.0-S0305737224001476-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142097999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathologic complete response in patients with localized soft tissue sarcoma treated with neoadjuvant therapy and its correlation with clinical outcomes: A systematic review","authors":"A. Boulouta ,&nbsp;A. Kyriazoglou ,&nbsp;I. Kotsantis ,&nbsp;P. Economopoulou ,&nbsp;M. Anastasiou ,&nbsp;A. Pantazopoulos ,&nbsp;M. Kyrkasiadou ,&nbsp;M. Moutafi ,&nbsp;N. Gavrielatou ,&nbsp;E. Zazas ,&nbsp;C. Caglar ,&nbsp;I. Nixon ,&nbsp;M. Tolia ,&nbsp;G. Kavourakis ,&nbsp;A. Psyrri","doi":"10.1016/j.ctrv.2024.102820","DOIUrl":"10.1016/j.ctrv.2024.102820","url":null,"abstract":"<div><p>Soft tissue sarcomas (STS), comprising approximately 1% of adult solid malignancies, are primarily treated with surgery, with the choice of perioperative treatment being a challenging and highly individualized decision. Clinical trials assessing neoadjuvant modalities in STS predominantly use clinical outcomes or radiologic response as endpoints, with pathologic complete response (pCR) not being employed as a designated study endpoint. Our systematic review aimed to assess the rates of pCR in clinical trials of different neoadjuvant modalities for STS and its correlation with patient clinical outcomes. 23 phase I, II and III studies were included, from which data regarding rates of pCR with each treatment, as well as correlation of pCR with clinical outcomes were retrieved. In 16 trials that assessed pCR, the percentage of patients who achieved a pCR ranged from 8 to 58%. Most of these trials did not aim to establish an association between pCR and clinical outcomes. However, among those that did investigate this correlation, a positive association was identified between pCR and both 5-year disease-specific survival (DSS) and 5-year overall survival (OS). While pCR serves as a crucial marker guiding treatment decisions in other neoplasms like triple negative breast cancer and urothelial cancer, it is not yet used in a similar setting for STS. Our findings indicate variability in patients achieving pCR across different neoadjuvant treatments for STS and a possible positive correlation with patient outcomes. Consequently, we propose considering pCR as a surrogate endpoint in future prospective trials for STS.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"130 ","pages":"Article 102820"},"PeriodicalIF":9.6,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review","authors":"Alberto Zambelli ,&nbsp;Laura Cortesi ,&nbsp;Mariangela Gaudio ,&nbsp;Grazia Arpino ,&nbsp;Giampaolo Bianchini ,&nbsp;Francesco Caruso ,&nbsp;Saverio Cinieri ,&nbsp;Giuseppe Curigliano ,&nbsp;Lucia Del Mastro ,&nbsp;Sabino De Placido ,&nbsp;Alessandra Fabi ,&nbsp;Lucio Fortunato ,&nbsp;Daniele Generali ,&nbsp;Alessandra Gennari ,&nbsp;Stefania Gori ,&nbsp;Giovanni Grandi ,&nbsp;Valentina Guarneri ,&nbsp;Marco Klinger ,&nbsp;Lorenzo Livi ,&nbsp;Caterina Marchiò ,&nbsp;Michelino De Laurentiis","doi":"10.1016/j.ctrv.2024.102815","DOIUrl":"10.1016/j.ctrv.2024.102815","url":null,"abstract":"<div><p>The introduction of PARP inhibitors has revolutionized the management and treatment of patients with pathogenic germline variants of BRCA1/2 who have developed breast cancer. The implementation of PARP inhibitors in clinical settings can be challenging due to their overlapping indications with other drugs, including both recently approved medications and those with proven efficacy. This study utilized the Delphi method to present the first Italian consensus regarding genetic testing, the use of PARP inhibitors in both early and metastatic settings, and strategies for managing the potential toxicity of these novel drugs. The Panel unanimously agreed on various issues, including the timing, techniques, and patient characteristics for BRCA1/2 genetic testing, and<!--> <!-->the appropriate placement of PARP inhibitors in the treatment algorithm for both early and advanced breast cancer. Nevertheless, some areas of divergence became evident, particularly regarding the use of axillary surgery for therapeutic purposes and the application of hormone replacement therapy in cases of bilateral mastectomy and risk-reducing salpingo-oophorectomy for patients treated for triple negative breast cancer. Additional research is needed in these particular domains to improve the care of patients with breast cancer who bear an increased genetic risk.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"130 ","pages":"Article 102815"},"PeriodicalIF":9.6,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224001439/pdfft?md5=bb46225d57e997e7ba8f276e713fd50a&pid=1-s2.0-S0305737224001439-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142088943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives","authors":"Erman Akkus ,&nbsp;Çağatay Arslan ,&nbsp;Yüksel Ürün","doi":"10.1016/j.ctrv.2024.102818","DOIUrl":"10.1016/j.ctrv.2024.102818","url":null,"abstract":"<div><p>Despite improvements in survival, metastatic castration-resistant prostate cancer (mCRPC) remains a significant clinical challenge. While taxanes, new hormonal agents, radiopharmaceuticals, and PARP inhibitors offer valuable treatment options, this review explores the potential of platinum chemotherapies (carboplatin, cisplatin, and oxaliplatin) as alternative choices. Existing research demonstrates promising preliminary results for platinum-based therapies in mCRPC showing PSA response rates (7.7–95 %) and improved overall survival (8–26.6 months). However, chemotherapy-related cytopenias are a frequent side effect. Further research is underway to evaluate the efficacy of platinum regimens against specific mCRPC histopathological variants, particularly aggressive subtypes where the carboplatin and cabazitaxel combination is already recommended. The unique DNA-targeting action of platinum therapy holds promise for patients with deficient DNA repair (dDDR), especially those with <em>BRCA</em> mutations. This potential is supported by both preclinical and ongoing clinical research. Given the limited success of immunotherapy in mCRPC, researchers are exploring the potential for platinum therapies to enhance its efficacy. Additionally, trials are investigating the synergy of combining platinum therapy with both immunotherapy and PARP inhibitors. Further exploration into the effectiveness of platinum therapies in specific mCRPC subpopulations, particularly those with dDDR, is crucial for optimizing their future use. In conclusion, this review highlights the promising potential of platinum-based chemotherapy as a valuable treatment option for mCRPC. While current evidence is encouraging, ongoing research is essential to further optimize its efficacy, identify optimal combinations with other therapies, and better understand its impact on specific mCRPC subpopulations.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"130 ","pages":"Article 102818"},"PeriodicalIF":9.6,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}